1. Rudd, R.M. Malignant mesothelioma. Br. Med. Bull. 2010, 93, 105–123. [CrossRef] [PubMed]
2. Bibby, A.C.; Tsim, S.; Kanellakis, N.; Ball, H.; Talbot, D.C.; Blyth, K.G.; Maskell, N.A.; Psallidas, I. Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment. Eur. Respir. Rev. 2016, 25, 472–486. [CrossRef] [PubMed]
3. Carioli, G.; Bonifazi, M.; Rossi, M.; Zambelli, A.; Franchi, M.; Zocchetti, C.; Gasparini, S.; Corrao, G.; La Vecchia, C.; Negri, E. Management and survival of pleural mesothelioma: A record linkage study. Respiration 2018, 95, 405–413. [CrossRef] [PubMed]
4. Sayan, M.; Eren, M.F.; Gupta, A.; Ohri, N.; Kotek, A.; Babalioglu, I.; Kaplan, S.O.; Duran, O.; Or, O.D.; Cukurcayir, F.; et al. Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm. Adv. Respir. Med. 2019, 87, 289–297. [CrossRef] [PubMed]
5. Olsen, N.J.; Franklin, P.J.; Reid, A.; de Klerk, N.H.; Threlfall, T.J.; Shilkin, K.; Musk, B. Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med. J. Aust. 2011, 195, 271–274. [CrossRef] [PubMed]
6. Frank, A.L.; Joshi, T.K. The global spread of asbestos. Ann. Glob. Health 2014, 80, 257–262. [CrossRef] [PubMed]
7. Hashim, D.; Boffetta, P. Occupational and environmental exposures and cancers in developing countries. Ann. Glob. Health 2014, 80, 393–411. [CrossRef]
8. Kindler, H.L.; Ismaila, N.; Armato, S.G.; Bueno, R.; Hesdorffer, M.; Jahan, T.; Jones, C.M.; Miettinen, M.; Pass, H.; Rimner, A.; et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 2018, 36, 1343–1373. [CrossRef]
9. Quintanilla, M.; Montero, L.M.; Renart, J.; Villar, E.M. Podoplanin in inflammation and cancer. Int. J. Mol. Sci. 2019, 20, 707. [CrossRef]
10. Kato, Y.; Kaneko, M.K.; Kuno, A.; Uchiyama, N.; Amano, K.; Chiba, Y.; Hasegawa, Y.; Hirabayashi, J.; Narimatsu, H.; Mishima, K.; et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 2006, 349, 1301–1307. [CrossRef]
11. Kato, Y.; Kaneko, M.K.; Kunita, A.; Ito, H.; Kameyama, A.; Ogasawara, S.; Matsuura, N.; Hasegawa, Y.; Suzuki-inoue, K.; Inoue, O.; et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 2008, 99, 54–61. [CrossRef] [PubMed]
12. Abe, S.; Morita, Y.; Kaneko, M.K.; Hanibuchi, M.; Tsujimoto, Y.; Goto, H.; Kakiuchi, S.; Aono, Y.; Huang, J.; Sato, S.; et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J. Immunol. 2013, 190, 6239–6249. [CrossRef] [PubMed]
13. Mitsunaga, M.; Ogawa, M.; Kosaka, N.; Rosenblum, L.T.; Choyke, P.L.; Kobayashi, H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 2011, 17, 1685–1691. [CrossRef] [PubMed]
14. Sato, K.; Nagaya, T.; Choyke, P.L.; Kobayashi, H. Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: Preclinical experience. Theranostics 2015, 5, 698–709. [CrossRef]
15. Sato, K.; Hanaoka, H.; Watanabe, R.; Nakajima, T.; Choyke, P.L.; Kobayashi, H. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. Mol. Cancer Ther. 2014, 14, 141–150. [CrossRef]
16. Sato, K.; Watanabe, R.; Hanaoka, H.; Harada, T.; Nakajima, T.; Kim, I.; Paik, C.H.; Choyke, P.L.; Kobayashi, H. Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Mol. Oncol. 2014, 8, 620–632. [CrossRef]
17. Nagaya, T.; Nakamura, Y.; Sato, K.; Zhang, Y.F.; Ni, M.; Choyke, P.L.; Ho, M.; Kobayashi, H. Near infrared photoimmunotherapy with an anti-mesothelin antibody. Oncotarget 2016, 7, 23361–23369. [CrossRef]
18. Sato, K.; Nakajima, T.; Choyke, P.L.; Kobayashi, H. Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Adv. 2015, 5, 25105–25114. [CrossRef]
19. Sato, K.; Ando, K.; Okuyama, S.; Moriguchi, S.; Ogura, T.; Totoki, S.; Hanaoka, H.; Nagaya, T.; Kokawa, R.; Takakura, H.; et al. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: A mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy. ACS Cent. Sci. 2018, 4, 1559–1569. [CrossRef]
20. Kobayashi, H.; Choyke, P.L. Near-infrared photoimmunotherapy of cancer. Acc. Chem. Res. 2019, 52, 2332–2339. [CrossRef]
21. Isobe, Y.; Sato, K.; Nishinaga, Y.; Takahashi, K.; Taki, S.; Yasui, H.; Shimizu, M.; Endo, R.; Koike, C.; Kuramoto, N.; et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. EBioMedicine 2020, 52, 102632. [CrossRef] [PubMed]
22. Sato, K.; Nagaya, T.; Mitsunaga, M.; Choyke, P.L.; Kobayashi, H. Near infrared photoimmunotherapy for lung metastases. Cancer Lett. 2015, 365, 112–121. [CrossRef] [PubMed]
23. Sato, K.; Nagaya, T.; Nakamura, Y.; Harada, T.; Choyke, P.L.; Kobayashi, H. Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model. Oncotarget 2015, 6, 19747–19758. [CrossRef]
24. Sato, K.; Choyke, P.L.; Hisataka, K. Selective cell elimination from mixed 3D culture using a near infrared photoimmunotherapy technique. J. Vis. Exp. 2016, 2016, 8–11. [CrossRef] [PubMed]
25. Sato, K.; Gorka, A.P.; Nagaya, T.; Michie, M.S.; Nakamura, Y.; Nani, R.R.; Coble, V.L.; Vasalatiy, O.V.; Swenson, R.E.; Choyke, P.L.; et al. Effect of charge localization on the: In vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates. Mol. Biosyst. 2016, 12, 3046–3056. [CrossRef]
26. Sato, K.; Gorka, A.P.; Nagaya, T.; Michie, M.S.; Nani, R.R.; Nakamura, Y.; Coble, V.L.; Vasalatiy, O.V.; Swenson, R.E.; Choyke, P.L.; et al. Role of fluorophore charge on the in vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates. Bioconjug. Chem. 2016, 27, 404–413. [CrossRef]
27. Sato, K.; Nagaya, T.; Nakamura, Y.; Harada, T.; Nani, R.R.; Shaum, J.B.; Gorka, A.P.; Kim, I.; Paik, C.H.; Choyke, P.L.; et al. Impact of C4’-O-Alkyl linker on in vivo pharmacokinetics of near-infrared cyanine/monoclonal antibody conjugates. Mol. Pharm. 2015, 12, 3303–3311. [CrossRef]
28. Sato, K.; Choyke, P.L.; Kobayashi, H. Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model. PLoS ONE 2014, 9, e113276. [CrossRef]
29. Sato, K.; Watanabe, T.; Wang, S.; Kakeno, M.; Matsuzawa, K.; Matsui, T.; Yokoi, K.; Murase, K.; Sugiyama, I.; Ozawa, M.; et al. Numb controls E-cadherin endocytosis through p120 catenin with aPKC. Mol. Biol. Cell 2011, 22, 3103–3119. [CrossRef]
30. Usami, N.; Fukui, T.; Kondo, M.; Taniguchi, T.; Yokoyama, T.; Mori, S.; Yokoi, K.; Horio, Y.; Shimokata, K.; Sekido, Y.; et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006, 97, 387–394. [CrossRef]
31. Kawaguchi, K.; Murakami, H.; Taniguchi, T.; Fujii, M.; Kawata, S.; Fukui, T.; Kondo, Y.; Osada, H.; Usami, N.; Yokoi, K.; et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009, 30, 1097–1105. [CrossRef]
32. Ordóñez, N.G. D24-0 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum. Pathol. 2005, 36, 372–380. [CrossRef] [PubMed]
33. Padgett, D.M.; Cathro, H.P.; Wick, M.R.; Mills, S.E. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am. J. Surg. Pathol. 2008, 32, 123–127. [CrossRef] [PubMed]
34. Hu, Y.; Yang, Q.; McMahon, L.A.; Wang, H.L.; Xu, H. Value of D24-0 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor. Appl. Immunohistochem. Mol. Morphol. 2010, 18, 411–413. [PubMed]
35. Zalcman, G.; Mazieres, J.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Moro-Sibilot, D.; Molinier, O.; Corre, R.; Monnet, I.; Gounant, V.; et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016, 387, 1405–1414. [CrossRef]
36. Lievense, L.A.; Sterman, D.H.; Cornelissen, R.; Aerts, J.G. Checkpoint blockade in lung cancer and mesothelioma. Am. J. Respir. Crit. Care Med. 2017, 196, 274–282. [CrossRef] [PubMed]
37. Balar, A.V.; Weber, J.S. PD-1 and PD-L1 antibodies in cancer: Current status and future directions. Cancer Immunol. Immunother. 2017, 66, 551–564. [CrossRef] [PubMed]
38. Nicolini, F.; Bocchini, M.; Bronte, G.; Delmonte, A.; Guidoboni, M.; Crinò, L.; Mazza, M. Malignant pleural mesothelioma: State-of-the-art on current therapies and promises for the future. Front. Oncol. 2020, 9. [CrossRef]
39. Kato, Y.; Kaneko, M.K. A Cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci. Rep. 2014, 4, 5924. [CrossRef]
40. Pula, B.; Witkiewicz, W.; Dziegiel, P.; Podhorska-Okolow, M. Significance of podoplanin expression in cancer-associated fibroblasts: A comprehensive review. Int. J. Oncol. 2013, 42, 1849–1857. [CrossRef] [PubMed]
41. Ugorski, M.; Dziegiel, P.; Suchanski, J. Podoplanin—A small glycoprotein with many faces. Am. J. Cancer Res. 2016, 6, 370–386. [PubMed]
42. Kitano, H.; Kageyama, S.I.; Hewitt, S.M.; Hayashi, R.; Doki, Y.; Ozaki, Y.; Fujino, S.; Takikita, M.; Kubo, H.; Fukuoka, J. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch. Pathol. Lab. Med. 2010, 134, 1520–1527. [PubMed]
43. Danielli, R.; Patuzzo, R.; Ruffini, P.A.; Maurichi, A.; Giovannoni, L.; Elia, G.; Neri, D.; Santinami, M. Armed antibodies for cancer treatment: A promising tool in a changing era. Cancer Immunol. Immunother. 2015, 64, 113–121. [CrossRef] [PubMed]
44. Sudo, H.; Tsuji, A.B.; Sugyo, A.; Saga, T.; Kaneko, M.K.; Kato, Y.; Higashi, T. Therapeutic efficacy evaluation of radioimmunotherapy with 90Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma. Cancer Sci. 2019, 110, 1653–1664. [CrossRef] [PubMed]
45. Wayne, A.S.; Fitzgerald, D.J.; Kreitman, R.J.; Pastan, I. Antibody derivatives as new therapeutics for hematologic. Immunotoxins for leukemia. Blood 2015, 123, 2470–2478. [CrossRef]
46. Pacheco, J.M.; Camidge, D.R. Antibody drug conjugates in thoracic malignancies. Lung Cancer 2018, 124, 260–269. [CrossRef]
47. Ito, K.; Mitsunaga, M.; Nishimura, T.; Saruta, M.; Iwamoto, T.; Kobayashi, H.; Tajiri, H. Near-Infrared photochemoimmunotherapy by photoactivatable bifunctional antibody-drug conjugates targeting human epidermal growth factor receptor 2 positive cancer. Bioconjug. Chem. 2017, 28, 1458–1469. [CrossRef]
48. Okada, M.; Kijima, T.; Aoe, K.; Kato, T.; Fujimoto, N.; Nakagawa, K.; Takeda, Y.; Hida, T.; Kanai, K.; Imamura, F.; et al. Clinical efficacy and safety of nivolumab: Results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin. Cancer Res. 2019, 25, 5485–5492. [CrossRef]
49. Sato, K.; Sato, N.; Xu, B.; Nakamura, Y.; Nagaya, T.; Choyke, P.L.; Hasegawa, Y.; Kobayashi, H. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci. Transl. Med. 2016, 8, 352ra110. [CrossRef]